Stroke Prevention in Atrial Fibrillation

Introduction to Anticoagulation Therapy

The American Heart Association recommends oral anticoagulation with warfarin or direct oral anticoagulants as the standard of care for patients with atrial fibrillation at moderate to high risk of stroke, with a reduction in stroke risk of 62-68% 1, 2, 3

The American College of Cardiology recommends warfarin (target INR 2.0-3.0) as a first-line treatment for patients with atrial fibrillation, reducing stroke risk by 62-68% 2, 3
Direct oral anticoagulants may be considered as an alternative to warfarin, with some studies showing superior efficacy and fewer bleeding events, although the evidence is not fully established, as suggested by the American Heart Association 2
Apixaban was significantly better than warfarin, with fewer overall strokes and major bleeding events, as demonstrated in the ARISTOTLE trial, and superior to aspirin alone for preventing stroke or systemic embolism in patients deemed unsuitable for warfarin therapy, as shown in the AVERROES study 4

Aspirin monotherapy is recommended only for low-risk patients or those who cannot take anticoagulants, providing modest protection with a 19-30% stroke reduction compared to placebo, as recommended by the American Family Physician and the American College of Cardiology 2, 5, 6
Aspirin appears to prevent non-disabling strokes more than disabling strokes, according to the European Society of Cardiology, and offers modest protection against stroke in atrial fibrillation patients, with a 19% stroke reduction (95% CI: 2% to 34%) compared to placebo 5, 6
Dual antiplatelet therapy with clopidogrel and aspirin may be considered for high-risk patients unsuitable for anticoagulation, offering more protection than aspirin alone but with increased bleeding risk, as recommended by the American Heart Association, but is not recommended as first-line therapy by the American College of Cardiology 1, 7

For patients with atrial fibrillation and stable coronary artery disease, oral anticoagulation alone is suggested rather than the combination of anticoagulation and aspirin, according to the American College of Chest Physicians 8
A time-limited approach may be warranted for patients with recent acute coronary syndrome or PCI, including triple therapy (OAC + DAPT) for 1-3 months, followed by dual therapy with OAC plus single antiplatelet up to 12 months, then OAC monotherapy, as suggested by the American College of Chest Physicians 8
For most AF patients on apixaban, apixaban monotherapy without aspirin is recommended, as suggested by the American College of Cardiology, but aspirin should be discontinued unless there is a specific indication such as recent acute coronary syndrome or coronary stenting within the past 1-4 weeks 9, 8

Individual risk varies over time, so the need for anticoagulation must be reevaluated at regular intervals, as recommended by the European Society of Cardiology 6
For patients with atrial fibrillation at low risk of stroke (CHADS₂ score of 0), no antithrombotic therapy is suggested as the first option, but if desired, aspirin (75-325 mg daily) may be considered over oral anticoagulation, according to the American College of Chest Physicians 10
For patients with atrial fibrillation at intermediate risk (CHADS₂ score of 1), oral anticoagulation is recommended over no therapy, aspirin, or combination therapy, as supported by the American College of Chest Physicians 10
For patients with atrial fibrillation at high risk (CHADS₂ score of ≥ 2), oral anticoagulation is strongly recommended over no therapy, aspirin, or combination therapy, as supported by the American College of Chest Physicians and the American Heart Association 10, 11

For AF patients with recent coronary stenting, a time-limited approach is recommended: discontinue aspirin after 1-4 weeks while maintaining P2Y12 inhibitor plus apixaban, continue P2Y12 inhibitor plus apixaban for up to 12 months, and transition to apixaban monotherapy thereafter, according to the American College of Cardiology 9, 8
For patients at high bleeding risk, dual therapy (OAC + single antiplatelet) may be preferred from the outset, according to the American College of Cardiology 9
Triple therapy for up to 4 weeks may be reasonable for patients with high thrombotic risk and low bleeding risk, but the default should be dual antithrombotic therapy (P2Y12 inhibitor plus DOAC), as recommended by the American College of Cardiology 9